Product Information
Cartalax 20mg is a synthetic tripeptide bioregulator (Ala-Glu-Asp; sequence “AED”) developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Preclinical studies suggest it modulates fibroblast proliferation markers (Ki-67), reduces pro-apoptotic signaling (p53, caspase-3), and supports extracellular matrix homeostasis. Administered via subcutaneous injection, each vial contains 20mg of high-purity Cartalax. Note: Published human dosage is limited; content is provided for educational purposes based on preclinical and observational data.
| Specification | Value |
|---|---|
| Product Name | Cartalax |
| Peptide Type | Synthetic Tripeptide |
| Alternative Names | AED Peptide, T-31 |
| Amino Acid Sequence | Ala-Glu-Asp |
| Three-Letter Code | AED |
| Molecular Formula | C₁₂H₁₉N₃O₈ |
| Molecular Weight | 333.29 g/mol |
| PubChem CID | 87815447 |
| CAS Number | N/A — Not Universally Assigned |
| Physical Form | Lyophilized Powder |
| Purity | Refer to Batch-Specific COA |
| Research Category | Cartilage, Connective Tissue & Cellular Aging Research |
| Intended Use | Laboratory Research Use Only |
Specification
Value
Product Name:
N/A
Compound Type:
N/A
CAS Number:
N/A
PubChem CID:
N/A
Molecular Formula:
N/A
Molecular Weight (g/mol):
N/A
Amino Acid Count:
N/A
Amino Acid Sequence:
N/A
Synonyms / Other Names:
N/A
Appearance:
N/A
Purity:
N/A
Solubility:
N/A
Storage — Sealed:
N/A
Storage — After Reconstitution:
N/A
